Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

GetSimpli Oral Semaglutide offers a promising solution for those looking to enhance their overall well-being, manage their weight, and improve metabolic health. As an innovative sublingual tablet ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

A first randomized clinical trial shows that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss and lower insulin requirements. Semaglutide (known by its ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.

Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...

Specifically, semaglutide (2.4 mg) improved obesity-related HF symptoms in people with inflammation and both with and without atrial fibrillation (AFib), plus improved cardiac structure and function.

Researchers have established that the application of once-weekly semaglutide in patients with type 2 diabetes (T2D) increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION). A ...

A July 2024 study published in JAMA Ophthalmology found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a higher risk of a rare eye condition known as "eye stroke," or non ...

The EMA is reviewing Danish studies linking semaglutide to increased NAION risk, following a request from the Danish Medicines Agency. Semaglutide, a GLP-1 receptor agonist, is approved for obesity ...